Ownership and insider activity for REGENXBIO Inc. (RGNX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system.
Price
| Price | $7.98 |
| Market Cap | $413M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $24.8M | $46.7M | $75.6M | $69.5M | $338.4M | $345.2M | $97.0M | $34.5M | $57.5M | $34.5M |
| Short-term Investments | $64.7M | $114.1M | $244.2M | $226.7M | $137.3M | $112.2M | $267.7M | $240.7M | $177.2M | $195.6M |
| Receivables | $1.0M | $473000 | $8.6M | $38.1M | $43.0M | $32.4M | $30.3M | $26.3M | $21.6M | $27.4M |
| Inventory | $1.8M | $5.3M | $5.7M | 0 | $10.5M | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $93.4M | $168.0M | $337.9M | $345.0M | $531.2M | $518.8M | $416.0M | $335.0M | $278.0M | $281.3M |
| Property, Plant & Equipment | $9.3M | $14.0M | $28.7M | $39.1M | $120.3M | $192.5M | $206.8M | $192.6M | $171.3M | $152.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $172.7M | $198.7M | $543.8M | $497.9M | $708.2M | $1.11B | $833.3M | $574.0M | $466.0M | $453.0M |
| Accounts Payable | $1.5M | $4.8M | $4.4M | $6.4M | $10.6M | $11.4M | $27.2M | $22.8M | $22.8M | $21.4M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $47.9M |
| Total Current Liabilities | $9.7M | $14.4M | $22.2M | $33.7M | $81.4M | $130.5M | $130.4M | $130.3M | $103.2M | $118.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $147.4M |
| Total Liabilities | $11.0M | $15.6M | $35.0M | $47.7M | $330.4M | $349.6M | $317.1M | $262.2M | $206.3M | $350.3M |
| Retained Earnings | -$114.6M | -$187.8M | -$83.0M | -$177.8M | -$289.1M | -$161.2M | -$441.6M | -$705.0M | -$932.1M | -$1.13B |
| Total Equity | $161.7M | $183.0M | $508.8M | $450.2M | $377.8M | $764.3M | $516.2M | $311.7M | $259.7M | $102.7M |
| Total Debt | 0 | 0 | $5.9M | $11.3M | $72.7M | $86.7M | $94.8M | $89.3M | $82.0M | $260.5M |
| Net Debt | -$89.6M | -$160.8M | -$313.9M | -$284.9M | -$403.1M | -$370.8M | -$269.8M | -$186.0M | -$152.7M | $30.4M |
| Working Capital | $83.7M | $153.6M | $315.7M | $311.4M | $449.8M | $388.4M | $285.5M | $204.7M | $174.8M | $163.2M |
Financial Health
| Debt / Equity | 0.96 |
| Current Ratio | 2.86 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.57 |
Profitability
| Return on Equity | -220.07% |
| Return on Invested Capital | -52.72% |
| Return on Assets | -50.81% |
| Gross Margin | 54.22% |
| Operating Margin | -94.08% |
| Net Margin | -112.58% |
Related companies: ABSI · CRVS · FDMT · GOSS · KALV · MLTX · OLMA
Explore sector: Healthcare · Biotechnology
More sections of RGNX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks